Cigna Investments Inc. New Raises Stock Holdings in Humana Inc (NYSE:HUM)

Cigna Investments Inc. New grew its stake in shares of Humana Inc (NYSE:HUM) by 102.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,298 shares of the insurance provider’s stock after purchasing an additional 3,701 shares during the quarter. Cigna Investments Inc. New’s holdings in Humana were worth $2,292,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HUM. Tompkins Financial Corp bought a new position in shares of Humana during the fourth quarter valued at $55,000. Convergence Investment Partners LLC bought a new stake in Humana during the 4th quarter valued at approximately $206,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in Humana by 135.5% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 664 shares of the insurance provider’s stock valued at $243,000 after purchasing an additional 382 shares during the period. J.W. Cole Advisors Inc. bought a new stake in Humana during the 4th quarter valued at approximately $338,000. Finally, Nicolet Advisory Services LLC bought a new stake in Humana in the 4th quarter worth approximately $205,000. Institutional investors and hedge funds own 93.22% of the company’s stock.

In related news, Director David A. Jr/Ky Jones sold 5,800 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $256.19, for a total transaction of $1,485,902.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.42% of the company’s stock.

Shares of HUM traded down $0.84 during trading hours on Friday, hitting $394.43. The company had a trading volume of 415,854 shares, compared to its average volume of 962,079. The company has a market capitalization of $52.26 billion, a PE ratio of 20.25, a price-to-earnings-growth ratio of 1.73 and a beta of 0.91. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.49. Humana Inc has a one year low of $208.25 and a one year high of $412.70. The company’s fifty day moving average price is $361.93 and its two-hundred day moving average price is $345.82.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $5.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.84 by $0.56. Humana had a return on equity of 21.02% and a net margin of 3.86%. The firm had revenue of $18.94 billion during the quarter, compared to analyst estimates of $18.49 billion. During the same period in the previous year, the company posted $4.48 EPS. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. Analysts forecast that Humana Inc will post 18.55 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.625 per share. This represents a $2.50 annualized dividend and a yield of 0.63%. The ex-dividend date is Monday, June 29th. Humana’s dividend payout ratio is currently 13.99%.

HUM has been the topic of a number of research reports. Citigroup lifted their price objective on Humana from $424.00 to $435.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Goldman Sachs Group reiterated a “buy” rating and issued a $425.00 target price on shares of Humana in a report on Monday, January 27th. Cantor Fitzgerald lifted their target price on Humana from $345.00 to $400.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Morgan Stanley lifted their target price on Humana from $375.00 to $500.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, Barclays restated a “buy” rating on shares of Humana in a report on Sunday, March 29th. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $405.42.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Technical Indicators – What is a Golden Cross?

Want to see what other hedge funds are holding HUM? Visit to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.